Comparing Nkarta (NASDAQ:NKTX) & TuHURA Biosciences (NASDAQ:HURA)

Nkarta (NASDAQ:NKTX) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings for Nkarta and TuHURA Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1	0	4	1	2.83
TuHURA Biosciences	1	0	5	0	2.67

Nkarta currently has a consensus target price of $10.75, suggesting a potential upside of 414.35%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 314.75%. Given Nkarta’s stronger consensus rating and higher probable upside, research analysts clearly believe Nkarta is more favorable than TuHURA Biosciences.

Earnings & Valuation

This table compares Nkarta and TuHURA Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08 million	($1.34)	-1.56
TuHURA Biosciences	N/A	N/A	-$30.05 million	($0.61)	-3.56

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 9.8% of Nkarta shares are owned by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Nkarta has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500.

Profitability

This table compares Nkarta and TuHURA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Summary

Nkarta beats TuHURA Biosciences on 9 of the 12 factors compared between the two stocks.

About Nkarta

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.